Understanding and Preventing Liver Damage from a Leukemia Medication
Mechanistic Study of PEG-asparaginase-Induced Liver Injury
This research explores why a key leukemia medicine, PEG-asparaginase, causes liver damage in adults and looks for ways to prevent it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11176991 on NIH RePORTER |
What this research studies
PEG-asparaginase is a very important medicine for treating acute lymphoblastic leukemia (ALL) in children, but it often causes liver problems in adults, limiting its use. Our team is working to understand exactly how this medicine harms the liver, using advanced laboratory models. We believe that by uncovering the specific biological steps involved in this liver injury, we can find new ways to protect adult patients. The goal is to make this life-saving leukemia treatment safer and more effective for everyone.
Who could benefit from this research
Good fit: Patients with Acute Lymphoblastic Leukemia, especially adults, who may need treatment with PEG-asparaginase, are the ultimate beneficiaries of this research.
Not a fit: Patients without Acute Lymphoblastic Leukemia or those not treated with PEG-asparaginase would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies or medications that prevent liver damage, allowing more adult patients with ALL to safely receive PEG-asparaginase.
How similar studies have performed: This foundational work builds upon preliminary data from the research team, suggesting a novel approach to understanding this drug-induced liver injury.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Fernandez, Christian Antonio — University of Pittsburgh at Pittsburgh
- Study coordinator: Fernandez, Christian Antonio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.